Pharmaceuticals

Wed, 08/25/2010 - 13:27

Aoxing Pharma secures SFDA approval to test addiction drug

Shanghai. August 25. INTERFAX-CHINA - Hebei Province-based Aoxing Pharmaceutical Co. Inc. has been approved by the State Food and Drug Administration (SFDA) to start clinical trials of a buprenorphine-naloxone sublingual tablet used to treat opiate addiction, the company announced Aug. 24.

This article is only accessible to Interfax subscribers. To gain access to this article, as well similar in-depth articles and industry-specific content, please contact our sales staff by telephone (+852 2537 2262) .

Start free trial NOW